spacer
home > ebr > winter 2018 > situation critical
PUBLICATIONS
European Biopharmaceutical Review

Situation Critical

In February 2017, the Boston Consulting Group published Breaking Through the Wall – a report calling for concerted action on antibiotics R&D and the creation of a global union for antibiotics R&D. One of its most shocking statistics was the number of scientists on the ground working globally in antibiotics research – less than 500 in the industry worldwide. Since the report came out, further job reductions have been announced, and fewer than 100 antimicrobial resistance (AMR) researchers are now estimated to remain in the UK industry. This figure is particularly alarming in comparison with the number of scientists working in other fields. For example, Cancer Research UK is reported to fund more than 4,000 research scientists in the UK alone.

The low number of researchers is one of a long list of worrying figures in AMR. Cases of antibiotic-resistant infections have been rising steeply over the past 15 years, with almost 60% of Escherichia coli infections now resistant to penicillins. Lord O’Neill’s AMR review predicted that, by 2050, AMR will account for over 10 million deaths per year worldwide, more than those attributable to cancer. By the same year, if no new antibiotics are developed, the impact on the global economy will be $100 trillion.

Warning signs are already present that the future pipeline of new treatments is in danger. According to intellectual property lawyers Marks and Clerk, antibiotic patent applications worldwide dropped by over a half from 2004 to 2013. Additionally, fewer new drugs are emerging from clinical trials, with only two new molecular entities being approved by US regulators between 2008 and 2012, down from 16 in the early 1980s. Most worryingly of all, no new classes of antibiotics that are effective against the most serious gram-negative infections have been introduced in 55 years.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Peter Jackson is an experienced UK-based serial entrepreneur in the life sciences sector. Over the past 10 years, he has created six new companies, targeting novel therapeutics across infection, oncology and immunology, as well as in agrochemicals and life sciences services. Peter has over 25 years’ experience in the sector, previously holding senior executive roles as Commercial Director then Vice President of Avecia’s Pharmaceutical Products business unit, following senior commercial and R&D positions at predecessor companies Zeneca and ICI. During 2015-16, Peter was chairman of the steering committee created to establish the UK’s translational R&D centre focused on antimicrobial resistance, the AMR Centre, and now runs the enterprise as its executive director.
spacer
Dr Peter Jackson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.
More info >>

White Papers

Competitive Drive: The Challenges of a Globalised Packaging Industry

Aesica Pharmaceuticals

Packaging is becoming an increasingly competitive and lucrative industry globally. Jeremy Drummond PhD of Aesica Formulated Products looks at the challenges and opportunities this presents.
More info >>

 
Industry Events

4th Annual Genome Editing Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 4thAnnual Genome Editing Congress taking place on 8-9 November 2018 in London. As part of our Genomics and Synthetic Biology UK series, our congress will bring together Over 600 delegates representing internationally renowned research & academic institutions, clinical research institutions and pharmaceutical companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement